Akademik Veri Yönetim Sistemi
Nuclear Medicine Seminars, cilt.6, sa.3, ss.385-396, 2021 (Scopus)
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and PSMA-directed radioligand therapy (RLT) with Lutetium-177 (Lu-177) PSMA is promising systemic modality, which involves the delivery of targeted radiation therapy in the form of β-particles to sites of tumour tissue. Although, Lu-177 PSMA RLT has been recently introduced for castration-resistant metastatic prostate cancer (CRMPC), has continuously increasing interest and use in many centers. Therapy is well tolerated with relatively few side effects and has a positive effect on overall survival and quality of life. The purpose of this guideline is to assist nuclear medicine specialists in evaluating and managing patients with RCMPC for whom RLT using Lu-177 PSMA as an “unproven intervention in clinical practice”, in accordance with the best currently available knowledge.